Early Stage Investment.
Opportunity in a fast-growing market.
The Trans-Duodenal Barrier developed by TDC is a patented endoscopic transduodenal bypass implant for combined diabetes/obesity therapy that atraumatically prevents nutrient absorption in the duodenum and delays gastric emptying.
The present prototype has successfully completed initial animal studies (ZIM-funded). Following successful CE certification, commercialization as a class IIb product is expected to start in 2027.
The Trans-Duodenal Barrier is a globally unique product for the pronounced growth market of obesity, DMT2 and NASH (approx. 800 million patients worldwide) and already has a sales potential in the billions at 0.1% penetration.
The uniqueness of the Trans-Duodenal Barrier is based in particular on the patented method of fixation and therefore also allows much broader use than previous methods for combining restrictive and malabsorptive principles of action.
million diabetes patients in the EU
million patients with fatty liver disease
million obesity patients
Strong upward trend
Treatment methods to date
- Ineffective because usually not effective in the long term
- “unpopular” because a very high personal contribution is required
- Medication: not yet successful despite immense investment in research
- Effective, but irreversible
- Lifelong aftercare, therefore expensive
- Unclear long-term consequences
Implements experience from surgery: Malabsorptive procedures more effective than restrictive procedures alone
Simple implantation as part of an outpatient gastroscopy with i.v. sedaton (propofole)
No anesthesia, no X-ray fluoroscopy, no medication required
Proven efficacy in type 2 diabetes, probable efficacy in fatty liver and obesity
Reversible, repeatable, combinable
Completion of prototype design
Start of clinical trial
Completion of clinical study
CE certification, preparation for marketing
Start of 3 multicenter PM studies
Development of marketing
Completion of multicenter PM studies